Immune Checkpoint Inhibitors Trigger and Exacerbate Anti-CV2/CRMP5 Paraneoplastic Neurologic Syndromes.
ICIs may trigger the onset and exacerbate the progression of CV2/CRMP5-PNS. Post-ICI forms are clinically undistinguishable but possibly more severe than their ICI-naïve counterparts. Increased surveillance is needed in identifying preexisting PNSs, with extreme caution when considering ICI treatment. Post-ICI-induced PNSs have variable prognosis according to the associated onconeural autoantibodies.
Authors
- Antonio Farina (ORCID: https://orcid.org/0000-0002-5551-0185)
- Cristina Birzu (ORCID: https://orcid.org/0000-0002-6781-7301)
- Marie Bénaiteau (ORCID: https://orcid.org/0009-0005-2347-6006)
- Géraldine Picard (ORCID: https://orcid.org/0000-0003-1282-267X)
- Dimitri Psimaras (ORCID: https://orcid.org/0000-0002-6641-288X)
- Macarena Villagrán‐García (ORCID: https://orcid.org/0000-0001-9236-2428)
- Véronique Rogemond (ORCID: https://orcid.org/0000-0003-2098-920X)
- Jérôme Honnorat (ORCID: https://orcid.org/0000-0002-4721-5952)
- Giulia Sofia Cereda (ORCID: https://orcid.org/0000-0002-2110-092X)
- Bastien Joubert (ORCID: https://orcid.org/0000-0003-4631-3056)
- Arnaud Sautereau
- Melih Bayrak
Institutions
- Université Claude Bernard Lyon 1 (FR)
- INSEAD (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospices Civils de Lyon (FR)
- Pitié-Salpêtrière Hospital (FR)
- Institut du Cerveau (FR)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- PubMed
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1212/nxi.0000000000200446
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00